

Mycopathologia (2010) 169:175–182  
DOI 10.1007/s11046-009-9246-0

## Examination of Potential Virulence Factors of *Candida tropicalis* Clinical Isolates From Hospitalized Patients

Melyssa Negri · Margarida Martins ·  
Mariana Henriques · Terezinha I. E. Svidzinski ·  
Joana Azeredo · Rosário Oliveira

Received: 27 July 2009 / Accepted: 3 October 2009 / Published online: 23 October 2009  
© Springer Science+Business Media B.V. 2009

**Abstract** *Candida tropicalis* has been reported to be one of the *Candida* species which is most likely to cause bloodstream and urinary tract infections in hospitalized patients. Accordingly, the aim of this study was to characterize the virulence of *C. tropicalis* by assessing antifungal susceptibility and comparing the expression of several virulence factors. This study was conducted with seven isolates of *C. tropicalis* from urine and blood cultures and from central venous catheter. *C. tropicalis* ATCC 750 was used as reference strain. Yeasts adhered (2 h) to epithelial cells and silicone and 24 h biofilm biomass were determined by crystal violet staining. Pseudohyphae formation ability was determined after growth in fetal bovine serum. Enzymes production (hemolysins, proteases, phospholipases) was assessed by halo formation on agar plates. Susceptibility to antifungal agents was determined by E-test. Regarding adhesion, it can be highlighted that *C. tropicalis* strains adhered significantly more to epithelium than to silicone. Furthermore, all

*C. tropicalis* strains were able to form biofilms and to express total hemolytic activity. However, protease was only produced by two isolates from urine and by the isolates from catheter and blood. Moreover, only one *C. tropicalis* (from catheter) was phospholipase positive. All isolates were susceptible to voriconazole, fluconazole and amphotericin B. Four strains were susceptible-dose dependent to itraconazole and one clinical isolate was found to be resistant.

**Keywords** *Candida tropicalis* · Virulence factors · Secretion of enzymes · Biofilm · Adhesion

### Introduction

Fungal hospital infections (FHI) incidence has increased significantly over the last decades. *Candida* species are the most frequently isolated fungi, corresponding to approximately 80% of FHI, being the fourth responsible for blood stream infection and the overwhelming majority responsible for urinary tract infections [1–3].

Usually, *Candida tropicalis* is considered the third *Candida* species most frequently isolated from urine cultures [4, 5]. Moreover, in a recent epidemiological study conducted in 12 Brazilian medical centers, *C. tropicalis* was the second most frequent *Candida* species, accounting for 20–24% of all candidemias [2, 6]. Additionally, *C. tropicalis* is often found in patients admitted in intensive care units (ICUs),

M. Negri · M. Martins · M. Henriques (✉) ·  
J. Azeredo · R. Oliveira

IBB-Institute for Biotechnology and Bioengineering,  
Centre of Biological Engineering, Universidade do  
Minho, Campus de Gualtar, 4710-057 Braga, Portugal  
e-mail: mcrh@deb.uminho.pt

T. I. E. Svidzinski  
Teaching and Research in Clinical Analysis Laboratory,  
Division of Medical Mycology, Universidade Estadual de  
Maringá, Av. Colombo, 5790, Maringá,  
Paraná 87020-900, Brazil

especially in patients with cancer or/and requiring prolonged catheterization, or receiving broad-spectrum antibiotics [2, 4, 6, 7].

Several virulence factors seem to be responsible for *C. tropicalis* infections, which present high potential for dissemination and mortality [8, 9]. Adhesion to host surfaces (epithelial cells and medical devices), as well as biofilm formation, are considered the first step to initiate *Candida* infection [10, 11]. Furthermore, secretion of enzymes (proteases and phospholipases), as well as hemolytic activity, are recognized as important factors in tissue invasion [10–14].

Hence, the aim of this study was to assess and compare the expression of different virulence factors (enzymes secretion, adhesion and biofilm formation and pseudohyphae production) by several *C. tropicalis* clinical isolates. Moreover, antifungal susceptibility was also determined in order to deeply characterize the virulence of *C. tropicalis*.

## Materials and Methods

### Isolates

This study was conducted with seven isolates of *C. tropicalis*: five obtained from candiduria, one from candidemia and one from a central venous catheter (CVC) and all were from patients admitted to ICUs at the University Hospital (UH) in Maringá, Paraná, Brazil. *C. tropicalis* ATCC 750 was used as reference strain.

### Isolation and Identification

Yeasts were isolated according to hospital routine methods. To perform hemoculture, one volume of blood was inoculated in 10 volumes of Trypticase Soy Broth (Difco, Detroit, Michigan, EUA) and incubated in the automatic BACTEC (Becton–Dickinson Microbiology Systems, Sparks, MD) system. Urine was spread using a calibrated loop (10  $\mu$ l) on CLED medium agar plates (Difco) and incubated at 37°C for 48 h. CVC isolated yeasts underwent a well established technique [15]. Briefly, CVC was rolled on blood agar plates (Difco) and incubated at 35°C for 72 h. After yeast growth, they were subcultured in CHROMagar *Candida*<sup>®</sup> (CHROMagar, BioMerieux, Paris, France) to assess the purity of the culture and the

color of the colonies. From this selective and differential medium, yeasts were identified by three methods: the MicroScan rapid yeast identification panel (Dade Behring Inc, CA, USA), the classical biochemical method [16] and molecular identification.

*Candida* DNA was extracted using the QIAamp<sup>®</sup> DNA Mini Kit (QIAGEN, IZASA, Lisboa, Portugal) according to the manufacturer's instructions. DNA content was determined by spectrophotometry readings at 260 nm. Aliquots of 10  $\mu$ l were analyzed by electrophoresis in a 0.8% agarose (Bio-Rad, Lisboa, Portugal) gel in 1 $\times$  TBE buffer (Bio-Rad) and visualized with a UV transilluminator after ethidium bromide (Bio-Rad) staining (0.5 mg/ml). To assess *Candida* speciation, a polymerase chain reaction (PCR) method previously described [17] was used. Specific primers for the genomic sequences of DNA topoisomerase II of *C. albicans*, *C. dubliniensis*, *C. tropicalis* (genotypes I and II), *C. parapsilosis* (genotypes I and II), *C. krusei*, *C. kefyr*, *C. guilliermondii* and *C. glabrata* were used.

### Adhesion and Biofilm Formation

Yeast cells were grown at 37°C, 120 rpm for 18 h on Sabouraud Dextrose Broth (SDB; Difco) and Phosphate saline buffer (PBS)—washed suspensions of each yeast culture were resuspended in RPMI 1640 (Sigma, Saint Louis, Missouri, USA) to a final concentration of  $1.0 \times 10^7$  cells/ml. Then, 3 ml of the suspension was added to each well of a 6-well plate containing either a confluent layer of TCC-SUP human urinary bladder epithelial cell line (DSMZ—German Collection of Microorganisms and Cell Cultures) or a silicone coupon (2  $\times$  2 cm) (Neves e Neves, Trofa, Portugal). All procedures were performed in triplicate and repeated in three separate assays.

### Quantification of Adhered Yeast Cells

After 2 h of incubation (120 rpm, at 37°C), the wells were washed twice with PBS to remove unattached yeasts. Yeast cells were quantified using the crystal violet (CV) staining method.

### Epithelial Cells

Three milliliters of CV stain (1%) was added to each well containing the epithelial cells with adherent

yeasts and allowed to stain for 5 min. Then, the wells were washed three times with PBS. In order to remove the CV stain from the epithelial cells, 3 ml of ethanol:acetone (1:1) was added to each well and removed immediately. Three milliliter of acetic acid (33%) was added to each well and the absorbance of the final solution was read at 570 nm in a microtitre plate reader (Bio-Tek® Synergy HT, IZASA). Wells containing epithelial cells without yeasts were used as controls. The mean absorbance of CV retained by yeasts was expressed as absorbance per unit of well area.

### Silicone

*Candida* cells adhered to silicone were quantified according to Henriques et al. [18]. Briefly, the coupons containing adherent yeasts were removed from each well and immersed for 5 min in new well plates containing 3 ml of methanol. After withdrawing the methanol, the coupons were allowed to dry at room temperature. Then, 3 ml of CV (1%) was added to each well and allowed to stain for 5 min. Coupons were transferred to a new well, washed with ultrapure water and immersed in 3 ml acetic acid (33%) to dissolve the stain. Coupons without yeasts were used as controls. The absorbance of the obtained solution was read in triplicate in a microtitre plate reader at 570 nm. The final number of cells attached, per coupon unit area, was determined using the mean absorbance and the respective calibration curves, previously established.

### Biofilm Biomass Quantification

After 24 h of incubation (120 rpm, at 37°C) *C. tropicalis* biofilm forming ability was assessed on inert materials through quantification of total biomass by CV staining as described above. Experiments were repeated in 3–5 independent assays.

### Pseudohyphae Formation

Pseudohyphae formation was defined as a cell bearing a rounded outgrowth with a length greater than or equal to the diameter of the parent cell, with a constriction at the base. The percentage of cells in pseudohyphae form, against blastospores, was determined by microscopy counting after 2 h of cell growth in a liquid medium containing equal volumes

of RPMI 1640 (Sigma) and fetal bovine serum (GIBCO, New York, USA). In these experiments, 100 cells per field were examined. Each experiment was conducted in triplicate.

### Protease and Phospholipase Secretion

Secretion of proteases and phospholipases was detected by the formation of an opaque halo of degradation around the colonies grown in a specific agar plate, according to Rùchel [19] and Price et al. [20], respectively. An aliquot (5 µl) of a  $1 \times 10^8$  cells/ml suspension prepared in distilled water was inoculated on protease agar medium (2% agar, 1.17% yeast carbon base, 0.01% yeast extract and 0.2% bovine serum albumin) pH 5.0 and on phospholipase agar (2% agar, 1% peptone, 2% glucose, 1 M NaCl, 5 mM CaCl<sub>2</sub>·2H<sub>2</sub>O and 8% egg yolk) and the Petri dishes were incubated for 7 days at 37°C. The enzymatic activity (Pz) was determined by the ratio between the colony diameter and the colony diameter plus the halo zone as described by Price et al. [20]. Each experiment was conducted in triplicate.

### Hemolytic Activity

Hemolysin production was evaluated using a modification of the plate assay described by Luo et al. [13]. Fresh cultured colonies of *C. tropicalis* were obtained after being spread on Sabouraud Dextrose Agar (SDA; Difco) (18–24 h). Then, a suspension was prepared in saline solution (0.9% NaCl) to reach  $10^8$  cells/ml, enumerated using a Neubauer chamber. Ten microliters of this suspension was spot-inoculated on sugar-enriched sheep blood (2% peptone, 1% agar, 7% fresh sheep blood, 3% glucose) and the plates were incubated at 37°C. After 48 h they were classified as absent (no halo), partial, or total (completely transparent halo) hemolytic activity. The assay was conducted in quadruplicate on two separate occasions for each yeast isolate tested. A standard strain, *C. albicans* ATCC 90028, was used as control in each experiment.

### Antifungal Susceptibility Test Methods

The E-test method was used as recommended by the manufacturer with strips, provided by AB BIODISK

(Solna, Sweden), having the following concentrations: from 0.002 to 256  $\mu\text{g/ml}$ ; for fluconazole (FLU) and from 0.002 to 32  $\mu\text{g/ml}$  for itraconazole (ITR), voriconazole (VO) and amphotericin B (AMB). The minimum inhibitory concentrations (MIC) of drugs were determined on RPMI 1640 (Sigma) agar with 2% glucose. An inoculum suspension was adjusted to a turbidity of 0.5 McFarland standard ( $1 \times 10^6$  to  $5 \times 10^6$  cells/ml) and was incubated at 37°C for 48 h. MICs were read as the lowest concentration at which the border of the elliptical inhibition zone intercepted the scale on the strip. Quality control was performed in accordance with the Clinical and Laboratory Standards Institute (CLSI) document M27-A3 [21], using *Candida krusei* ATCC 6258 and *C. parapsilosis* ATCC 22019. MIC interpretative criteria was performed according to the CLSI M27-A3 [21]: (a) FLU: MIC  $\leq 8$   $\mu\text{g/ml}$ —susceptible (S);  $16 < \text{MIC} < 32$   $\mu\text{g/ml}$ —susceptible-dose dependent (S-DD) and MIC  $\geq 64$   $\mu\text{g/ml}$ —resistant (R); (b) ITR: MIC  $\leq 0.125$   $\mu\text{g/ml}$ —S;  $0.25 < \text{MIC} < 0.5$   $\mu\text{g/ml}$ —S-DD and MIC  $\geq 1$   $\mu\text{g/ml}$ —R; (c) AMB MIC  $> 1$   $\mu\text{g/ml}$ —R; (d) VO MIC  $\geq 1$   $\mu\text{g/ml}$ —S;  $\leq 2$   $\mu\text{g/ml}$ —R.


### Statistical Analysis

Results obtained were analyzed using the SPSS (Statistical Package for the Social Sciences) program. One-way ANOVA with the Bonferroni test was used to compare the number of adherent cells of the several strains assayed. All tests were performed with a confidence level of 95%.

## Results

A total of seven *C. tropicalis* isolates was used in this study: five obtained from urine samples, one from blood samples and one from CVC, all from patients admitted to ICUs at the UH of Maringá, Paraná, Brazil. Additionally, all the methods (MicroScan rapid yeast identification panel, classical biochemical and molecular identification) used had identified *C. tropicalis* with 100% concordance (data not shown).


Regarding adhesion ability (Fig. 1), it can be highlighted that all *C. tropicalis* adhered in a significantly greater extent ( $P < 0.05$ ) to epithelial cells than to silicone. Considering the differences among the isolates, it is possible to observe from



**Fig. 1** Number of *C. tropicalis* cells per  $\text{cm}^2$  ( $n^\circ \text{ cell/cm}^2$ ) (mean  $\pm$  standard deviation) adhered to TCC-SUP epithelial cells and to silicone measured by crystal violet staining. \* represents the statistical differences ( $P < 0.05$ ) of adhesion extension to TCC-SUP between the strain L012 and strains 1, 16, 29, 69, ATCC 750; \*\* represents the statistical differences ( $P < 0.05$ ) of adhesion extension to silicone of the strains 16 and 1 compared to the strains 29, 75, L012, ATCC 750

Fig. 1 that *C. tropicalis* L012, from CVC, adhered in a highest extent to epithelial cells ( $4.05 \times 10^6$  cells/ $\text{cm}^2$ ) with  $P < 0.001$  vs. strains 1, 16, 29, 69 and to silicone ( $9.37 \times 10^5$  cells/ $\text{cm}^2$ ) with  $P < 0.001$  vs. strains 1, 12, 69. Clinical isolates 29 and 69, from urine cultures, adhered to epithelial cells in lower number than other yeasts ( $P < 0.05$  vs. L012) and the latter, as well as strain 12, adhered in lower extent than other yeasts to silicone (Fig. 1).

As it can be observed in Fig. 2, all *C. tropicalis* were able to form biofilms and strains did not present significant statistical differences.



**Fig. 2** Biofilm biomass on silicone measured by crystal violet staining, expressed as absorbance (570 nm)/ $\text{cm}^2$  [Abs (570 nm)/ $\text{cm}^2$ ]. Mean  $\pm$  standard deviation

**Table 1** Comparison of putative virulence factors of *C. tropicalis* from clinical isolate, including proteolytic (Pro), phospholytic (Phos) and hemolysis (Hemo) activity and ability for pseudohyphae formation

Isolates		Activity			Pseudohyphae formation %
Sites	Strain	Pro <sup>a</sup>	Phos <sup>a</sup>	Hemo	
Urine	12	1.00	1.00	Total	10
Urine	16	0.81	1.00	Total	4
Urine	29	0.85	1.00	Total	3
Urine	75	1.00	1.00	Total	4
Urine	69	1.00	1.00	Total	1
CVC	L012	0.89	0.66	Total	7
Blood	1	0.69	1.00	Total	2

<sup>a</sup> Values of enzyme activity, according to Price et al. [20]: Pz = 1.00 means that the test strain is negative for enzymic activity, while a value of Pz < 1.00 means that the test strain is positive for enzyme activity

Concerning *C. tropicalis* pseudohyphae formation and enzymatic activity (Table 1), it was possible to verify that all isolates produced a low percentage of pseudohyphae formation. Among all, isolates 12 and L012 presented the highest production of pseudohyphae formation (10 and 7%, respectively). Nevertheless, all isolates were able to express total hemolytic activity on sheep-blood agar medium supplemented with glucose. However, protease was only produced by two isolates from urine and by the isolates from catheter and blood and only one *C. tropicalis* (from CVC) was phospholipase positive.

The levels of *C. tropicalis* isolates antifungal susceptibility are shown in Table 2. It is possible to observe that all isolates showed susceptibility (S) to VO, FLU and AMB. The largest percent of S-DD was observed for ITR in four strains and one clinical isolate from urine was found to be resistant (MIC = 1 µg/ml).

**Table 2** In vitro susceptibility of *C. tropicalis* from clinical isolates for amphotericin B (AMB), voriconazole (VO), itraconazole (ITR) and fluconazole (FLU)

Isolates		Susceptibility category (MIC µg/ml) <sup>a</sup>			
Sites	Strain	AMB	VO	ITR	FLU
Urine	12	S (0.5)	S (0.032)	S (0.064)	S (0.5)
Urine	16	S (0.25)	S (0.032)	S-DD (0.38)	S (0.5)
Urine	29	S (0.38)	S (0.023)	SDD (0.38)	S (0.5)
Urine	75	S (1)	S (0.064)	SDD (0.5)	S (0.125)
Urine	69	S (0.125)	S (0.125)	R (1)	S (2)
CVC	L012	S (0.003)	S (0.023)	SDD (0.25)	S (1)
Blood	1	S (0.047)	S (0.012)	S (0.032)	S (0.25)

<sup>a</sup> MIC interpretative criteria was performed according to the CLSI M27-A3 [21]

## Discussion

Nosocomial infections by Non-*Candida albicans* *Candida* (NCAC) species such as candidemia and candiduria have emerged as an increasing problem during the last two decades [22, 23]. Moreover, *C. tropicalis* appears to display higher potential for dissemination and mortality and possesses several virulence factors that can enhance the progression of infections than *C. albicans* and other NCAC species [6, 8, 24].

In the present study, the results of morphological and biochemical tests were in agreement with molecular identification. Morphological, serological, or biochemical tests have been used, along the years, for the identification of *Candida* species. However, misidentification has been reported specially in relation to *C. tropicalis* [3, 10]. Recently, molecular-based techniques, which are simpler and more efficient than the conventional tests, have been adapted to the identification of pathogenic microorganisms. In particular, due to its speed, reproducibility, high sensitivity and specificity, PCR tests have been increasingly used in laboratories for identification of several fungal species [3, 10, 17].

Concerning adhesion ability, it was possible to verify that all *C. tropicalis* adhered in a significantly higher extent ( $P < 0.05$ ) to epithelial cells than to silicone. Sohn et al. [25] compared the ability of *C. albicans* to adhere to the human colorectal carcinoma cell line Caco-2 and epidermoid vulvovaginal A431 cells and to polystyrene and reported that *C. albicans* adheres in high extent to polystyrene and both epithelia. According to Bendel and Hostetter [26], the extent of adhesion to the human epithelial cell line HeLa S3 did not differ between *C. albicans* and *C. tropicalis* despite both species having distinct

mechanisms for this process. Nevertheless, the present results clearly show differences in the adhesion ability among the different isolates and hence adhesion of *C. tropicalis* to biotic and abiotic surfaces is strain dependant. Different intra-species adherence ability was also reported by other authors for other *Candida* species [9, 27–29].

We did not find a clear relation between pseudohyphae formation and adhesion capability. Although *C. tropicalis* L012, from CVC, and strain 12, from urine, adhered in higher extent to epithelial cells presenting also more pseudohyphae formation, the strain 75 exhibited an intermediate pseudohyphae formation and high adhesion ability. On the other hand, clinical isolates 29 and 69, from urine cultures, adhered to epithelial cells and displayed pseudohyphae formation in a lower extent than the other strains. This evidences the current lack of knowledge concerning the adhesion mechanisms of NCAC species to epithelium, as well as about the factors affecting the adhesion process [18].

Adhesion of *Candida* spp. to hard materials or host cells has been considered as an early step in biofilm formation [30, 31]. Nevertheless, it is important to highlight that, although strains 69 and 12 adhered in small number than other yeasts to silicone (Fig. 1) they showed higher ability to form biofilms on this material (Fig. 2). This result is consistent with other studies [14, 32], reporting differences between adhesion and biofilm formation abilities on polystyrene and poly(vinyl chloride) (PVC) surfaces under static conditions, which also suggest that adhesion and biofilm formation of *C. tropicalis* are two distinct phenomena.

All *C. tropicalis* strains tested were able to form biofilms on silicone, which has important clinical impact once biofilm-associated infections are difficult to treat, representing a source of reinfections [23, 33]. Previous works also reported that *C. tropicalis* can form extensive in vitro biofilms in PVC catheters [34] and polystyrene surfaces [33].

The infective ability of yeasts depends on specific virulence mechanisms that confer the ability to colonize host surfaces, to invade deeper host tissue or to evade host defences [8, 35, 36]. During the pathogenic process many virulence attributes may be involved including production of extracellular proteases and phospholipases, as well as hemolytic activity [10–14, 37, 38]. In this study, all isolates were able to

express total hemolytic activity. Manns et al. [12] demonstrated that *C. albicans* produced hemolytic activity and Luo et al. [13] observed that NCAC species are capable of producing one or more types of hemolysins in vitro with differences among species. Moreover, they observed that *C. tropicalis* was able to produce complete hemolysis after 48 h, corroborating the results obtained herein.

In the present case, only few isolates were protease and phospholipase positive, corroborating the results of other authors [10, 39]. In opposition, Kumar et al. [38] detected 100 and 72.9% of proteases and phospholipase producers, respectively, among *Candida* spp. isolated from pulmonary tuberculosis patients. According to these results, protease and phospholipase expression can vary according to *Candida* species, strain and the site of isolation. Furthermore, although the methods used to test the presence of these enzymes are simple and fast they are not excessively accurate, specially compared with molecular methods that can detect gene expression [24, 36].

Concerning antifungal susceptibility results, all isolates were susceptible to VO, FLU and AMB and for four strains were S-DD for ITR. However, one clinical isolate showed to be resistant to ITR. These results are comparable to those reported in the literature, with slight differences that were dependent on the underlying disease and the *Candida* species involved in the infection [10, 14, 40, 41].

Though some authors have already assessed some *C. tropicalis* virulence factors, this work gathers, for the first time, the most important ones: secretion of enzymes, pseudohyphae formation, adhesion (to epithelial cells and silicone), biofilm formation and antifungal susceptibility. Despite it was not possible to establish a relation among the virulence factors assayed, it is interesting to notice that the strain isolated from CVC (L012) presented higher levels of all these factors. Furthermore, all clinical isolates presented one or more virulence factors.

## References

1. Lundstrom T, Sobel J. Nosocomial candiduria: a review. *Clin Infect Dis*. 2001;32:1602–7. doi:10.1086/320531.
2. Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta DA, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia

- in eleven medical centers. *J Clin Microbiol.* 2006;44:2816–23. doi:10.1128/JCM.00773-06.
3. Asmundsdottir LR, Erlendsdottir H, Haraldsson G, Guo H, Xu J, Gottfredsson M. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. *Clin Infect Dis.* 2008;47:17–24. doi:10.1086/589298.
  4. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. *Clin Infect Dis.* 2000;30:14–8. doi:10.1086/313583.
  5. Álvarez-Lerma F, Nolla-Salas J, León C, Palomar M, Jordá R, Carrasco N, et al. Candiduria in critically ill patients admitted to intensive care medical units. *Intensive Care Med.* 2003;29:1069–76. doi:10.1007/s00134-003-1807-y.
  6. Nucci M, Colombo AL. Candidemia due to *Candida tropicalis*: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. *Diagn Microbiol Infect Dis.* 2007;58:77–82. doi:10.1016/j.diagmicrobio.2006.11.009.
  7. Rho J, Shin JH, Song JW, Park MR, Kee SJ, Jang SJ, et al. Molecular investigation of two consecutive nosocomial clusters of *Candida tropicalis* candiduria using pulsed-field gel electrophoresis. *J Microbiol.* 2004;42:80–6.
  8. Krcmery V, Barnes AJ. Non-albicans *Candida* spp. causing fungaemia: pathogenicity and antifungal resistance. *J Hosp Infect.* 2002;50:243–60. doi:10.1053/jhin.2001.1151.
  9. Okawa Y, Miyauchi M, Kobayashi H. Comparison of pathogenicity of various *Candida tropicalis* strains. *Biol Pharm Bull.* 2008;31:1507–10.
  10. Furlaneto-Maia L, Specian A, Bizerra F, de Oliveira M, Furlaneto M. In vitro evaluation of putative virulence attributes of oral isolates of *Candida* spp. obtained from elderly healthy individuals. *Mycopathologia.* 2008;166:209–17. doi:10.1007/s11046-008-9139-7.
  11. Tamura NK, Negri MFN, Bonassoli LA, Svidzinski TIE. Fatores de virulência de *Candida* spp isoladas de cateteres venosos e mãos de servidores hospitalares. *Rev Soc Bras Med Trop.* 2007;40:91–3. doi:10.1590/S0037-86822007000100021.
  12. Manns JM, Mosser DM, Buckley HR. Production of a hemolytic factor by *Candida albicans*. *Infect Immun.* 1994;62:5154–6. doi:10.1590/S0037-86822009000200029.
  13. Luo G, Samaranyake LP, Yau JYY. *Candida* species exhibit differential in vitro hemolytic activities. *J Clin Microbiol.* 2001;39:2971–4. doi:10.1128/JCM.39.8.2971-2974.2001.
  14. Bizerra FC, Nakamura CV, de Poersch C, Estivalet Svidzinski TI, Borsato Quesada RM, Goldenberg S, et al. Characteristics of biofilm formation by *Candida tropicalis* and antifungal resistance. *FEMS Yeast Res.* 2008;8:442–50. doi:10.1111/j.1567-1364.2007.00347.x.
  15. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-catheter-related infection. *N Engl J Med.* 1977;296:1305–9.
  16. Kurtzman CP, Fell JW (1998) The yeasts, a taxonomics. 4th ed. Elsevier Science.
  17. Kanbe T, Horii T, Arishima T, Ozeki M, Kikuchi A. PCR-based identification of pathogenic *Candida* species using primer mixes specific to *Candida* DNA topoisomerase II genes. *Yeast.* 2002;19:973–89. doi:10.1002/yea.892.
  18. Henriques M, Azeredo J, Oliveira R. *Candida* species adhesion to oral epithelium: factors involved and experimental methodology used. *Crit Rev Microbiol.* 2006;32:217–26. doi:10.1080/10408410601023524.
  19. Rüchel R. Proteinases of pathogenic fungi. *Mycoses.* 1999;42:48–52.
  20. Price M, Wilkinson I, Gentry L. Plate method for detection of phospholipase activity in *Candida albicans*. *Sabouraudia.* 1982;20:7–14.
  21. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd edition (M27-A3). CLSI document M27-A3. Wayne, PA, USA: Clinical and Laboratory Standards Institute.
  22. Lai C-C, Tan C-K, Huang Y-T, Shao P-L, Hsueh P-R. Current challenges in the management of invasive fungal infections. *J Infect Chemother.* 2008;14:77–85. doi:10.1007/s10156-007-0595-7.
  23. Schelenz S. Management of candidiasis in the intensive care unit. *J Antimicrob Chemother.* 2008;61:31–4. doi:10.1093/jac/dkm430.
  24. Zaugg C, Borg-von Zepelin M, Reichard U, Sanglard D, Monod M. Secreted aspartic proteinase family of *Candida tropicalis*. *Infect Immun.* 2001;69:405–12. doi:10.1128/IAI.69.1.405-412.2001.
  25. Sohn K, Senyürek I, Fertey J, Königsdorfer A, Joffroy C, Hauser N, et al. An in vitro assay to study the transcriptional response during adherence of *Candida albicans* to different human epithelia. *FEMS Yeast Res.* 2006;6:1085–93. doi:10.1111/j.1567-1364.2006.00130.x.
  26. Bendel C, Hostetter M. Distinct mechanisms of epithelial adhesion for *Candida albicans* and *Candida tropicalis*. Identification of the participating ligands and development of inhibitory peptides. *J Clin Invest.* 1993;92:1840–9. doi:10.1172/JCI116775.
  27. Panagoda GJ, Ellepola ANB, Samaranyake LP. Adhesion of *Candida parapsilosis* to epithelial and acrylic surfaces correlates with cell surface hydrophobicity. *Mycoses.* 2001;44:29–35. doi:10.1046/j.1439-0507.2001.00611.x.
  28. Lyon PJ, Resende MA. Correlation between adhesion, enzyme production, and susceptibility to fluconazole in *Candida albicans* obtained from denture wearers. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2006;102:632–8. doi:10.1016/j.tripleo.2005.12.015.
  29. Henriques M, Azeredo J, Oliveira R. The involvement of physico-chemical interactions in the adhesion of *Candida albicans* and *Candida dubliniensis* to epithelial cells. *Mycoses.* 2007;50:391–6. doi:10.1111/j.1439-0507.2007.01387.x.
  30. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen *Candida albicans*: development, architecture, and drug resistance. *J Bacteriol.* 2001;183:5385–94. doi:10.1128/JB.183.18.5385-5394.2001.
  31. Douglas LJ. *Candida* biofilms and their role in infection. *Trends Microbiol.* 2003;11:30–6. doi:10.1016/S0966-842X(02)00002-1.
  32. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. Biofilms of non-*Candida albicans* *Candida* species: quantification, structure and matrix composition. *Med Mycol.* 2009;20:1–9. doi:10.1080/13693780802549594.

33. Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, et al. Biofilm production by isolates of *Candida* species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. *J Clin Microbiol.* 2002;40:1244–8. doi:[10.1128/JCM.40.4.1244-1248.2002](https://doi.org/10.1128/JCM.40.4.1244-1248.2002).
34. Hawser SP, Douglas LJ. Biofilm formation by *Candida* species on the surface of catheter materials in vitro. *Infect Immun.* 1994;62:915–21.
35. Yang Y. Virulence factors of *Candida* species. *J Microbiol Immunol Infect.* 2003;36:223–8.
36. Fu Y, Luo G, Spellberg BJ, Edwards JE Jr, Ibrahim AS. Gene overexpression/suppression analysis of candidate virulence factors of *Candida albicans*. *Eukaryot Cell.* 2008;7:483–92. doi:[10.1128/EC.00445-07](https://doi.org/10.1128/EC.00445-07).
37. da Costa K, Ferreira J, Komesu M, Candido R. *Candida albicans* and *Candida tropicalis* in oral candidosis: quantitative analysis, exoenzyme activity, and antifungal drug sensitivity. *Mycopathologia.* 2009;167:73–9. doi:[10.1007/s11046-008-9154-8](https://doi.org/10.1007/s11046-008-9154-8).
38. Kumar VG, Latha R, Vedhagiri K, Sathiamoorthi T, Jayarani G, Sasikala R, et al. Phospholipase C, proteinase and hemolytic activities of *Candida* spp. isolated from pulmonary tuberculosis patients. *J Mycol Med.* 2009;19:3–10. doi:[10.1016/j.mycmed.2008.11.002](https://doi.org/10.1016/j.mycmed.2008.11.002).
39. Gokce G, Cerikcioglu N, Yagci A. Acid proteinase, phospholipase, and biofilm production of *Candida* species isolated from blood cultures. *Mycopathologia.* 2007;164:265–9. doi:[10.1007/s11046-007-9053-4](https://doi.org/10.1007/s11046-007-9053-4).
40. Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. *Int J Antimicrob Agents.* 2008;32:511–4. doi:[10.1016/j.ijanti.2008.05.023](https://doi.org/10.1016/j.ijanti.2008.05.023).
41. Panizo MM, Reviákina V, Dolande M, Selgrad S. *Candida* spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. *Med Mycol.* 2009;47:137–43. doi:[10.1080/13693780802144339](https://doi.org/10.1080/13693780802144339).